AU2018205484B2 - Therapeutic anti-lgE antibodies and methods and compositions thereof - Google Patents

Therapeutic anti-lgE antibodies and methods and compositions thereof Download PDF

Info

Publication number
AU2018205484B2
AU2018205484B2 AU2018205484A AU2018205484A AU2018205484B2 AU 2018205484 B2 AU2018205484 B2 AU 2018205484B2 AU 2018205484 A AU2018205484 A AU 2018205484A AU 2018205484 A AU2018205484 A AU 2018205484A AU 2018205484 B2 AU2018205484 B2 AU 2018205484B2
Authority
AU
Australia
Prior art keywords
ser
val
thr
leu
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018205484A
Other languages
English (en)
Other versions
AU2018205484A1 (en
Inventor
Andrew Saxon
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixal Inc
University of California San Diego UCSD
Original Assignee
Sixal Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018205484(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sixal Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Sixal Inc
Publication of AU2018205484A1 publication Critical patent/AU2018205484A1/en
Application granted granted Critical
Publication of AU2018205484B2 publication Critical patent/AU2018205484B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018205484A 2017-01-06 2018-01-05 Therapeutic anti-lgE antibodies and methods and compositions thereof Active AU2018205484B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Publications (2)

Publication Number Publication Date
AU2018205484A1 AU2018205484A1 (en) 2019-08-01
AU2018205484B2 true AU2018205484B2 (en) 2024-11-21

Family

ID=62789396

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018205484A Active AU2018205484B2 (en) 2017-01-06 2018-01-05 Therapeutic anti-lgE antibodies and methods and compositions thereof

Country Status (6)

Country Link
US (2) US11518818B2 (https=)
EP (1) EP3565587A4 (https=)
JP (2) JP7128191B2 (https=)
AU (1) AU2018205484B2 (https=)
CA (1) CA3049967C (https=)
WO (1) WO2018129248A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
HK1048127A1 (en) 2000-01-14 2003-03-21 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
EP1718669A4 (en) * 2004-02-02 2007-10-10 Tanox Inc IDENTIFICATION OF NEW IGE EPITOPES
CN101203241B (zh) * 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
WO2015195631A1 (en) 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3089260A1 (en) * 2018-01-22 2019-07-25 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes

Also Published As

Publication number Publication date
EP3565587A1 (en) 2019-11-13
JP2022172170A (ja) 2022-11-15
US11518818B2 (en) 2022-12-06
EP3565587A4 (en) 2020-12-16
CA3049967A1 (en) 2018-07-12
US20190322766A1 (en) 2019-10-24
JP7128191B2 (ja) 2022-08-30
WO2018129248A1 (en) 2018-07-12
US20230090487A1 (en) 2023-03-23
CA3049967C (en) 2024-10-01
JP7461420B2 (ja) 2024-04-03
AU2018205484A1 (en) 2019-08-01
JP2020505334A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
US12398200B2 (en) Anti-allergen antibodies
CN106794129B (zh) 对il-21具有特异性的结合分子及其用途
JP6397938B2 (ja) Ｂリンパ球のＣＤ２３と架橋するが肥満細胞を感作しないヒト化抗ＩｇＥ抗体
CN109562167A (zh) 联合治疗
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
JP2022500457A (ja) Ｉｌ−１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
WO2023061390A1 (en) Treatment of ige-mediated diseases
JP2025093954A (ja) ヒト化抗－ｃ５ａ抗体
US10513561B2 (en) Anti-MYL9 antibody
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
CN104039832A (zh) 抗磷酰胆碱的新抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2021142276A1 (en) Human antibodies to rift valley fever virus
US20230090487A1 (en) Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
JP2022172170A5 (https=)
TW202513582A (zh) 過敏疾病的預防或治療藥
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
KR20240134385A (ko) 항-성장 분화 인자 15의 항체 분자 및 그의 응용

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)